Glucagon-like peptide-1: a potent regulator of food intake in humans

Background/Aims Studies in animals suggest a physiological role for glucagon-like peptide-1-(7–36)-amide (GLP-1) in regulating satiety. The role of GLP-1 in regulating food intake in man has, however, not been investigated. Subjects—Sixteen healthy male subjects were examined in a double blind placebo controlled fashion. Methods The effect of graded intravenous doses (0, 0.375, 0.75, and 1.5 pmol/kg/min) of synthetic human GLP-1 on food intake and feelings of hunger and satiety was tested in healthy volunteers. Results Graded GLP-1 infusions resulted in a dose dependent reduction in food intake (maximal inhibition 35%, p<0.001 vcontrol) and a similar reduction in calorie intake (32%; p<0.001). Fluid ingestion was also reduced by GLP-1 (18% reduction, p<0.01). No overt side effects were produced by GLP-1, but subjects experienced less hunger and early fullness in the period before a meal during GLP-1 infusion at the highest dose (p<0.05). Conclusions Intravenous infusions of GLP-1 decrease spontaneous food intake even at physiological plasma concentrations, implying an important role for GLP-1 in the regulation of the early satiety response in humans.

[1]  R. Devos,et al.  Recombinant mouse OB protein: evidence for a peripheral signal linking adiposity and central neural networks. , 1995, Science.

[2]  A. Astrup,et al.  Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. , 1998, The Journal of clinical investigation.

[3]  M. Pelleymounter,et al.  Effects of the obese gene product on body weight regulation in ob/ob mice. , 1995, Science.

[4]  G. P. Smith,et al.  Satiety: the roles of peptides from the stomach and the intestine. , 1986, Federation proceedings.

[5]  B. Göke,et al.  Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients. , 1995, Digestion.

[6]  Steven L. Cohen,et al.  Weight-reducing effects of the plasma protein encoded by the obese gene. , 1995, Science.

[7]  A. Shalev,et al.  Absence of short-term effects of glucagon-like peptide-1 and of hyperglycemia on plasma leptin levels in man. , 1997, Metabolism: clinical and experimental.

[8]  J. Lauder,et al.  Distribution of glucagonlike peptide I (GLP‐I), glucagon, and glicentin in the rat brain: An immunocytochemical study , 1988, The Journal of comparative neurology.

[9]  N. Read,et al.  Effect of ileal and intravenous infusions of fat emulsions on feeding and satiety in human volunteers. , 1985, Gastroenterology.

[10]  J. Holst,et al.  Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus. , 1992, The New England journal of medicine.

[11]  C. Beglinger,et al.  Role of circulating cholecystokinin in control of fat-induced inhibition of food intake in humans. , 1992, Gastroenterology.

[12]  S. Bloom,et al.  Glucagon‐like peptide‐1 (GLP‐1): a trial of treatment in non‐insulin‐dependent diabetes mellitus , 1997, European journal of clinical investigation.

[13]  B. Göke,et al.  Differential effects of subcutaneous GLP-1 on gastric emptying, antroduodenal motility, and pancreatic function in men. , 1997, Proceedings of the Association of American Physicians.

[14]  J. Holst,et al.  Potential Therapeutic Levels of Glucagon-Like Peptide I Achieved in Humans by a Buccal Tablet , 1996, Diabetes Care.

[15]  J. Jansen,et al.  Satiety effects of cholecystokinin in humans. , 1994, Gastroenterology.

[16]  P. J. Larsen,et al.  Distribution of GLP‐1 Binding Sites in the Rat Brain: Evidence that Exendin‐4 is a Ligand of Brain GLP‐1 Binding Sites , 1995, The European journal of neuroscience.

[17]  J. Holst,et al.  Rat parietal cell receptors for GLP-1-(7-36) amide: northern blot, cross-linking, and radioligand binding. , 1994, The American journal of physiology.

[18]  E. Blázquez,et al.  Characterization of high‐affinity receptors for truncated glucagon‐like peptide‐1 in rat gastric glands , 1990, FEBS letters.

[19]  D. Hörsch,et al.  Reciprocal Cellular Distribution of Glucagon‐like Peptide‐1 (GLP‐1) Immunoreactivity and GLP‐1 Receptor mRNA in Pancreatic Islets of Rat , 1997, Pancreas.

[20]  G. Abrams.  Neurosecretion and Brain Peptides , 1982, Neurology.

[21]  G. P. Smith,et al.  Cholecystokinin decreases food intake in rats. , 1973, Journal of comparative and physiological psychology.

[22]  C. Beglinger,et al.  Effect of intravenous human gastrin-releasing peptide on food intake in humans. , 1994, Gastroenterology.

[23]  J. Gibbs,et al.  The Actions of Bombesin‐like Peptides on Food Intake a , 1988, Annals of the New York Academy of Sciences.

[24]  G. P. Smith,et al.  C-terminal octapeptide of cholecystokinin decreases food intake in man. , 1981, The American journal of clinical nutrition.

[25]  A. Joyner,et al.  Glucose intolerance but normal satiety in mice with a null mutation in the glucagon–like peptide 1 receptor gene , 1996, Nature Medicine.

[26]  A. Bado,et al.  Cholecystokinin suppresses food intake in cats: Structure-activity characterization , 1988, Pharmacology Biochemistry and Behavior.

[27]  I. Valverde,et al.  Presence and characterization of glucagon-like peptide-1(7-36) amide receptors in solubilized membranes of rat adipose tissue. , 1993, Endocrinology.

[28]  G. P. Smith,et al.  Endogenous cholecystokinin reduces feeding in young rats. , 1990, Science.

[29]  D. Smith,et al.  A role for glucagon-like peptide-1 in the central regulation of feeding , 1996, Nature.

[30]  T. Hamaoka,et al.  Production of rabbit antibody specific for amino-terminal residues of cholecystokinin octapeptide (CCK-8) by selective suppression of cross-reactive antibody response. , 1982, Journal of immunological methods.

[31]  M. Byrne,et al.  Human Studies with Glucagon‐like‐peptide‐1: Potential of the Gut Hormone for Clinical Use , 1996, Diabetic medicine : a journal of the British Diabetic Association.

[32]  N. Read,et al.  Comparisons of the effects on satiety and eating behaviour of infusion of lipid into the different regions of the small intestine. , 1988, Gut.

[33]  G. P. Smith,et al.  Brain-gut peptides and the control of food intake. , 1981, Advances in biochemical psychopharmacology.

[34]  R. Young,et al.  Cholecystokinin Decreases Food Intake in Rats1 , 1997 .

[35]  J. Holst,et al.  Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. , 1993, The Journal of clinical investigation.

[36]  J. Holst,et al.  The inhibitory effect of glucagon-like peptide-1 (GLP-1) 7-36 amide on gastric acid secretion in humans depends on an intact vagal innervation. , 1997, Gut.

[37]  H. Raybould,et al.  Mechanisms of action of peripherally administered cholecystokinin octapeptide on brain stem neurons in the rat , 1988, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[38]  B. Göke,et al.  Gastric emptying and release of incretin hormones after glucose ingestion in humans. , 1996, The Journal of clinical investigation.

[39]  J. Morley,et al.  Evidence for a physiological role for CCK in the regulation of food intake in mice. , 1989, The American journal of physiology.